AbbVie expands board to 13, appoints Dr. John M. Carethers as Class II director

AbbVie Inc.

Board size increased from twelve to thirteen directors on October 14, 2026; Dr. John M. Carethers named a Class II director.
Carethers is Vice Chancellor for Health Sciences at University of California San Diego and was previously a director of Avantor, Inc.
Board determined Carethers is independent under NYSE section 303A.02 and AbbVie's Governance and Director Independence Guidelines.
He was appointed to the Public Policy and Sustainability Committee of the AbbVie board.
Compensation will follow independent-director terms disclosed in Exhibit 10.5 to AbbVie's Form 10-Q for the quarter ended March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.